HBK Sorce Advisory’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.07M Sell
157,717
-1,436
-0.9% -$37.6K 0.08% 92
2026
Q1
$4.09M Buy
159,153
+7,494
+5% +$200K 0.08% 89
2025
Q4
$4.13M Sell
151,659
-9,192
-6% -$232K 0.09% 90
2025
Q3
$3.92M Buy
160,851
+8,788
+6% +$217K 0.1% 87
2025
Q2
$3.69M Buy
152,063
+7,999
+6% +$187K 0.1% 90
2025
Q1
$3.65M Buy
144,064
+30,931
+27% +$809K 0.11% 87
2024
Q4
$3M Sell
113,133
-26,759
-19% -$726K 0.09% 101
2024
Q3
$4.05M Buy
139,892
+4,334
+3% +$126K 0.12% 78
2024
Q2
$3.79M Buy
135,558
+9,018
+7% +$248K 0.13% 74
2024
Q1
$3.51M Buy
126,540
+6,367
+5% +$177K 0.12% 87
2023
Q4
$3.46M Sell
120,173
-9,588
-7% -$290K 0.13% 81
2023
Q3
$4.3M Buy
129,761
+2,870
+2% +$101K 0.19% 65
2023
Q2
$4.65M Buy
126,891
+16,062
+14% +$625K 0.2% 67
2023
Q1
$4.52M Sell
110,829
-160,513
-59% -$6.93M 0.21% 63
2022
Q4
$13.9M Buy
271,342
+151,706
+127% +$7.27M 0.37% 41
2022
Q3
$5.24M Buy
119,636
+40,713
+52% +$1.98M 0.35% 47
2022
Q2
$4.14M Sell
78,923
-46,468
-37% -$2.37M 0.31% 45
2022
Q1
$6.49M Sell
125,391
-12,332
-9% -$640K 0.36% 43
2021
Q4
$8.13M Sell
137,723
-861
-0.6% -$42.7K 0.41% 38
2021
Q3
$5.96M Sell
138,584
-16,517
-11% -$732K 0.33% 41
2021
Q2
$6.07M Buy
155,101
+24,596
+19% +$956K 0.34% 42
2021
Q1
$4.73M Buy
130,505
+2,138
+2% +$75.9K 0.28% 52
2020
Q4
$4.72M Buy
128,367
+4,209
+3% +$154K 0.29% 47
2020
Q3
$4.32M Buy
124,158
+4,016
+3% +$141K 0.31% 45
2020
Q2
$3.73M Buy
120,142
+6,757
+6% +$230K 0.28% 55
2020
Q1
$3.51M Sell
113,385
-5,929
-5% -$202K 0.34% 41
2019
Q4
$4.43M Buy
119,314
+9,566
+9% +$341K 0.39% 46
2019
Q3
$3.74M Buy
109,748
+2,637
+2% +$95.9K 0.36% 53
2019
Q2
$4.4M Buy
107,111
+5,027
+5% +$200K 0.42% 41
2019
Q1
$4.11M Buy
102,084
+745
+0.7% +$29.8K 0.41% 46
2018
Q4
$4.2M Buy
101,339
+1,719
+2% +$71.4K 0.48% 41
2018
Q3
$4.17M Sell
99,620
-1,503
-1% -$57.9K 0.47% 37
2018
Q2
$3.48M Sell
101,123
-4,238
-4% -$145K 0.4% 50
2018
Q1
$3.55M Buy
105,361
+8,015
+8% +$276K 0.45% 41
2017
Q4
$3.35M Buy
97,346
+23,094
+31% +$787K 0.39% 45
2017
Q3
$2.52M Sell
74,252
-8,890
-11% -$286K 0.38% 42
2017
Q2
$2.65M Buy
+83,142
New +$2.62M 0.42% 38
2017
Q1
Sell
-82,415
Closed -$2.6M 385
2016
Q4
$2.54M Buy
82,415
+287
+0.3% +$8.76K 0.46% 38
2016
Q3
$2.64M Buy
82,128
+3,650
+5% +$122K 0.52% 30
2016
Q2
$2.62M Buy
78,478
+7,325
+10% +$234K 0.56% 27
2016
Q1
$2M Buy
71,153
+44,150
+164% +$1.26M 0.47% 31
2015
Q4
$827K Buy
27,003
+878
+3% +$27.6K 0.22% 72
2015
Q3
$779K Buy
26,125
+1,272
+5% +$40.8K 0.25% 56
2015
Q2
$791K Sell
24,853
-693
-3% -$22.6K 0.27% 60
2015
Q1
$843K Sell
25,546
-983
-4% -$31.3K 0.29% 57
2014
Q4
$783K Buy
26,529
+3,958
+18% +$113K 0.27% 64
2014
Q3
$633K Sell
22,571
-2,716
-11% -$76.2K 0.23% 64
2014
Q2
$712K Buy
25,287
+1,013
+4% +$28.9K 0.25% 60
2014
Q1
$740K Sell
24,274
-426
-2% -$12.7K 0.27% 57
2013
Q4
$718K Buy
24,700
+1,999
+9% +$58.2K 0.26% 56
2013
Q3
$619K Sell
22,701
-20,157
-47% -$548K 0.26% 59
2013
Q2
$1.14M Buy
+42,858
New +$1.18M 0.25% 63

Other funds holding PFE

HBK Sorce Advisory's PFE Position: Q2 2026 in Review

HBK Sorce Advisory reduced its Pfizer (PFE) stake by 0.9% in Q2 2026, selling an estimated $37.6K and leaving 157,717 shares worth $4.07M. The position accounts for 0.08% of the portfolio, ranked #92.

HBK Sorce Advisory first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.9M in Q4 2022. 1,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • HBK Sorce Advisory held 157,717 shares of Pfizer worth $4.07M as of Q2 2026.
  • HBK Sorce Advisory sold 1,436 Pfizer shares in Q2 2026, an estimated $37.6K.
  • Pfizer made up 0.08% of HBK Sorce Advisory's portfolio in Q2 2026, its #92 holding.
  • HBK Sorce Advisory first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • HBK Sorce Advisory's Pfizer position peaked at $13.9M in Q4 2022.
  • 1,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.